The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer
Abstract
CONTEXT Molecular biomarkers aim to address the established limitations of clinicopathologic factors to accurately risk stratify patients with prostate cancer (PCa). Questions remain as to whether sufficient evidence supports adoption of these biomarkers for clinical use. OBJECTIVE To perform a systematic review of the available evidence supporting the clinical utility of the Decipher genomic classifier (GC). EVIDENCE ACQUISITION The review was performed as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines by searching PubMed and conference abstracts from January 2010 to June 2020. Evidence was then graded using the criteria of Simon et al (Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst 2009;101:1446-52) and American Urology Association (AUA) criteria. EVIDENCE SYNTHESIS In total, 42 studies and 30407 patients were included. GC performance data were available for localized, postprostatectomy, nonmetastatic castration-resistant, and metastatic hormone-sensitive PCa as part of retrospective studies (n=12141), prospective registries (n=17053), and prospective and post hoc randomized trial analyses (n=1213). In 32 studies (n=12600), the GC was independently prognostic for all study endpoints (adverse pathology, biochemical failure, metastasis, and cancer-specific and overall survival) on multivariable analysis and improved the discrimination over standard of care in 24 studies (n=8543). GC use changed the management in active surveillance (number needed to test [NNT]=9) and postprostatectomy (NNT=1.5-4) settings in five studies (n=4331). Evidence strength was levels 1 and 2 by the Simon criteria for all disease states other than high-risk PCa, and grades A and B by AUA criteria depending on disease state. CONCLUSIONS Consistent data are now present from diverse levels of evidence, which when viewed together, have demonstrated clinical utility of the GC in PCa. The utility of the GC is strongest for intermediate-risk PCa and postprostatectomy decision-making. PATIENT SUMMARY In this paper, we review the evidence of the Decipher genomic classification tool for men with prostate cancer. We found consistent evidence that the test helps identify which cancers are more or less aggressive, which in turn aids in personalized treatment decision-making.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stewart, L. A., Clarke, M., Rovers, M., Riley, R. D., Simmonds, M., Stewart, G., & Tierney, J. F. (2015) · JAMA · doi:10.1001/jama.2015.3656 · Cited by 2,134
Cited by
Biomarkers in Cancer Detection, Diagnosis, and Prognosis
Das, S., Dey, M. K., Devireddy, R., & Gartia, M. R. (2023) · Sensors · doi:10.3390/s24010037 · Cited by 383
Dal Pra, A., Ghadjar, P., Hayoz, S., Liu, V. Y. T., Spratt, D. E., Thompson, D. J. S., Davicioni, E., Huang, H.-C., Zhao, X., Liu, Y., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.007 · Cited by 65
Self-citationSpratt, D. E., Liu, V. Y. T., Michalski, J., Davicioni, E., Berlin, A., Simko, J. P., Efstathiou, J. A., Tran, P. T., Sandler, H. M., Hall, W. A., et al. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.04.010 · Cited by 45
Self-citationGenomic classifiers and prognosis of localized prostate cancer: a systematic review
Boyer, M. J., Carpenter, D. J., Gingrich, J. R., Raman, S. R., Sirohi, D., Tabriz, A. A., Rompre-Broduer, A., Lunyera, J., Basher, F., Bitting, R. L., et al. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-023-00766-z · Cited by 22
Metadata
- Authors
- Jairath, N. K., Dal Pra, A., Vince, R., Dess, R. T., Jackson, W. C., Tosoian, J. J., McBride, S. M., Zhao, S. G., Berlin, A., Mahal, B. A., Kishan, A. U., Den, R. B., Freedland, S. J., Salami, S. S., Kaffenberger, S. D., Pollack, A., Tran, P., Mehra, R., Morgan, T. M., Weiner, A. B., Mohamad, O., Carroll, P. R., Cooperberg, M. R., Karnes, R. J., Nguyen, P. L., Michalski, J. M., Tward, J. D., Feng, F. Y., Schaeffer, E. M., & Spratt, D. E.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 79
- Issue
- 3
- Pages
- 374-383
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W3113153998
- Cited by
- 219
- References
- 1
- FWCI
- 4.91
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. https://app.cochat.ai/papers/10.1016/j.eururo.2020.11.021
- The paper
- Jairath, N. K., Dal Pra, A., Vince, R., Dess, R. T., Jackson, W. C., Tosoian, J. J., McBride, S. M., Zhao, S. G., Berlin, A., Mahal, B. A., Kishan, A. U., Den, R. B., Freedland, S. J., Salami, S. S., Kaffenberger, S. D., Pollack, A., Tran, P., Mehra, R., Morgan, T. M., . . . Spratt, D. E. (2021). A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. European Urology. https://doi.org/10.1016/j.eururo.2020.11.021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.